NASDAQ:PRTA - Prothena Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$12.30 -1.00 (-7.52 %)
(As of 03/24/2019 01:49 PM ET)
Previous Close$12.30
Today's Range$12.25 - $13.2750
52-Week Range$8.63 - $44.75
Volume350,290 shs
Average Volume362,474 shs
Market Capitalization$490.28 million
P/E Ratio-3.41
Dividend YieldN/A
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta for the treatment of Alzheimer's disease; ALECT2 for ALECT2 amyloidosis; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and Sortilin for frontotemporal dementia and neuro inflammation. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Celgene Corporation to develop new therapies for a range of neurodegenerative diseases. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dún Laoghaire, Ireland.

Receive PRTA News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:PRTA



Sales & Book Value

Annual Sales$950,000.00
Book Value$10.59 per share


Net Income$-155,650,000.00
Net Margins-16,297.91%


Market Cap$490.28 million
Next Earnings Date5/14/2019 (Estimated)

Prothena (NASDAQ:PRTA) Frequently Asked Questions

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

How were Prothena's earnings last quarter?

Prothena Co. PLC (NASDAQ:PRTA) announced its quarterly earnings data on Thursday, February, 14th. The biotechnology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.55) by $0.04. The biotechnology company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.28 million. Prothena had a negative net margin of 16,297.91% and a negative return on equity of 38.98%. View Prothena's Earnings History.

When is Prothena's next earnings date?

Prothena is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Prothena.

What price target have analysts set for PRTA?

9 brokers have issued 12 month price targets for Prothena's stock. Their predictions range from $12.00 to $87.00. On average, they expect Prothena's share price to reach $33.9671 in the next year. This suggests a possible upside of 176.2% from the stock's current price. View Analyst Price Targets for Prothena.

What is the consensus analysts' recommendation for Prothena?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Prothena.

What are Wall Street analysts saying about Prothena stock?

Here are some recent quotes from research analysts about Prothena stock:
  • 1. According to Zacks Investment Research, "Prothena's license agreement with Roche for prasinezumab is big positive as it not only boosts Prothena’s pipeline development but also provides it with funds in the form of research reimbursement and milestone payments. The company also entered into an agreement with Celgene to develop its pipeline which should boost investor sentiment given the latter’s expertise. However, Prothena suffered a major setback with the discontinuation of development of lead candidate NEOD001. Moreover, due to disappointing data from a phase Ib study, the company will not advance PRX003 into mid-stage development. Consequently, the company has decided to reduce its workforce by 57%. The lack of promising candidates is a concern. Shares have performed worse than the industry in the last six months. Estimates looks stable ahead of the Q4 earnings release. Prothena has a mixed record of earnings surprises in recent quarters." (2/13/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and 12-month PT of $18. With discontinuation of NEOD001 development announced in April (our report here), investors are likely to focus on PRX002/RG7935 development as a treatment for Parkinson’s disease (PD). The company has guided to expectation for data from the Phase 2 PASADENA trial in 2020. Release of pharmacodynamic data from lower-dose cohorts of ATTR amyloidosis treatment PRX004 are anticipated in 2019." (8/8/2018)

Has Prothena been receiving favorable news coverage?

News articles about PRTA stock have trended positive on Sunday, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Prothena earned a daily sentiment score of 2.1 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.

Who are some of Prothena's key competitors?

What other stocks do shareholders of Prothena own?

Who are Prothena's key executives?

Prothena's management team includes the folowing people:
  • Mr. Gene G. Kinney, Pres, CEO & Director (Age 50)
  • Mr. Tran B. Nguyen, CFO & COO (Age 45)
  • Mr. Arthur W. Homan, Chief Legal Officer & Company Sec. (Age 60)
  • Ms. Karin L. Walker, Chief Accounting Officer & Controller (Age 56)
  • Dr. Wagner M. Zago, Chief Scientific Officer (Age 46)

Who are Prothena's major shareholders?

Prothena's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (12.32%), BlackRock Inc. (8.42%), Dimensional Fund Advisors LP (3.19%), Dimensional Fund Advisors LP (3.19%), Bank of America Corp DE (1.33%) and Geode Capital Management LLC (1.24%). Company insiders that own Prothena stock include Christopher S Henney, Dennis J Selkoe, Gene G Kinney, Karin L Walker and Tara Nickerson. View Institutional Ownership Trends for Prothena.

Which institutional investors are selling Prothena stock?

PRTA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, FMR LLC, Pinnacle Associates Ltd., Squarepoint Ops LLC, Northern Trust Corp, California Public Employees Retirement System and Virtus ETF Advisers LLC. View Insider Buying and Selling for Prothena.

Which institutional investors are buying Prothena stock?

PRTA stock was purchased by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Norges Bank, Bank of New York Mellon Corp, Two Sigma Investments LP, Two Sigma Advisers LP and Geode Capital Management LLC. View Insider Buying and Selling for Prothena.

How do I buy shares of Prothena?

Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $12.30.

How big of a company is Prothena?

Prothena has a market capitalization of $490.28 million and generates $950,000.00 in revenue each year. The biotechnology company earns $-155,650,000.00 in net income (profit) each year or ($3.61) on an earnings per share basis.

What is Prothena's official website?

The official website for Prothena is

How can I contact Prothena?

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN L2, D02 T804. The biotechnology company can be reached via phone at 011-353-1236-2500 or via email at [email protected]

MarketBeat Community Rating for Prothena (NASDAQ PRTA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  418 (Vote Outperform)
Underperform Votes:  276 (Vote Underperform)
Total Votes:  694
MarketBeat's community ratings are surveys of what our community members think about Prothena and other stocks. Vote "Outperform" if you believe PRTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/24/2019 by Staff

Featured Article: What is an SEC Filing?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel